QIAGEN price target raised to $26 from $20 at RW Baird Baird raised its price target on QIAGEN following better than expected Q4 results. The firm cited higher guidance, tangible drivers of organic growth, and cash available for accretive use. Shares are Outperform rated.
News For QGEN From The Last 14 Days
Check below for free stories on QGEN the last two weeks.